BACKGROUND: The optimal approach to HIV-associated Kaposi sarcoma (HIV-KS) in sub-Saharan Africa is unknown. With large-scale rollout of highly active antiretroviral therapy (HAART) in South Africa, we hypothesized that survival in HIV-KS would improve and administration of chemotherapy in addition to HAART would be feasible and improve KS-specific outcomes. METHODS: We conducted a randomized, controlled, open-label trial with intention-to-treat analysis. Treatment-naive patients from King Edward VIII Hospital, Durban, South Africa, a public-sector tertiary referral center, with HIV-KS, but no symptomatic visceral disease or fungating lesions requiring urgent chemotherapy, were randomized to HAART alone or HAART and chemotherapy (CXT). HAART arm received stavudine, lamivudine, and nevirapine (Triomune; CXT arm received Triomune plus bleomycin, doxorubicin, and vincristine every 3 weeks. When bleomycin, doxorubicin, and vincristine were not available, oral etoposide (50-100 mg for 1-21 days of a 28-day cycle) was substituted. Primary outcome was overall KS response using AIDS Clinical Trial Group criteria 12 months after HAART initiation. Secondary comparisons included time to response, progression-free survival, overall survival, adverse events, HIV control, CD4 reconstitution, adherence, and quality of life. RESULTS:Fifty-nine subjects were randomized to HAART and 53 to CXT; 12-month overall KS response was 39% in the HAART arm and 66% in the CXT arm (difference, 27%; 95% confidence interval, 9%-43%; P = 0.005). At 12 months, 77% were alive (no survival difference between arms; P = 0.49), 82% had HIV viral load <50 copies per milliliter without difference between the arms (P = 0.47); CD4 counts and quality-of-life measures improved in all patients. CONCLUSIONS:HAART with chemotherapy produced higher overall KS response over 12 months, whereas HAART alone provided similar improvement in survival and select measures of morbidity. In Africa, with high prevalence of HIV and human herpes virus-8 and limited resources, HAART alone provides important benefit in patients with HIV-KS.
RCT Entities:
BACKGROUND: The optimal approach to HIV-associated Kaposi sarcoma (HIV-KS) in sub-Saharan Africa is unknown. With large-scale rollout of highly active antiretroviral therapy (HAART) in South Africa, we hypothesized that survival in HIV-KS would improve and administration of chemotherapy in addition to HAART would be feasible and improve KS-specific outcomes. METHODS: We conducted a randomized, controlled, open-label trial with intention-to-treat analysis. Treatment-naive patients from King Edward VIII Hospital, Durban, South Africa, a public-sector tertiary referral center, with HIV-KS, but no symptomatic visceral disease or fungating lesions requiring urgent chemotherapy, were randomized to HAART alone or HAART and chemotherapy (CXT). HAART arm received stavudine, lamivudine, and nevirapine (Triomune; CXT arm received Triomune plus bleomycin, doxorubicin, and vincristine every 3 weeks. When bleomycin, doxorubicin, and vincristine were not available, oral etoposide (50-100 mg for 1-21 days of a 28-day cycle) was substituted. Primary outcome was overall KS response using AIDS Clinical Trial Group criteria 12 months after HAART initiation. Secondary comparisons included time to response, progression-free survival, overall survival, adverse events, HIV control, CD4 reconstitution, adherence, and quality of life. RESULTS: Fifty-nine subjects were randomized to HAART and 53 to CXT; 12-month overall KS response was 39% in the HAART arm and 66% in the CXT arm (difference, 27%; 95% confidence interval, 9%-43%; P = 0.005). At 12 months, 77% were alive (no survival difference between arms; P = 0.49), 82% had HIV viral load <50 copies per milliliter without difference between the arms (P = 0.47); CD4 counts and quality-of-life measures improved in all patients. CONCLUSIONS: HAART with chemotherapy produced higher overall KS response over 12 months, whereas HAART alone provided similar improvement in survival and select measures of morbidity. In Africa, with high prevalence of HIV and human herpes virus-8 and limited resources, HAART alone provides important benefit in patients with HIV-KS.
Authors: Luz Martin-Carbonero; Ana Barrios; Pere Saballs; Guillem Sirera; Jesus Santos; Rosano Palacios; M Eulalio Valencia; Marta Alegre; Daniel Podzamczer; Juan González-Lahoz Journal: AIDS Date: 2004-08-20 Impact factor: 4.177
Authors: C Dupont; E Vasseur; A Beauchet; P Aegerter; H Berthé; P de Truchis; D Zucman; E Rouveix; P Saiag Journal: AIDS Date: 2000-05-26 Impact factor: 4.177
Authors: P S Gill; M Rarick; J A McCutchan; L Slater; B Parker; E Muchmore; M Bernstein-Singer; B Akil; B M Espina; M Krailo Journal: Am J Med Date: 1991-04 Impact factor: 4.965
Authors: Scott R Evans; Susan E Krown; Marcia A Testa; Timothy P Cooley; Jamie H Von Roenn Journal: J Clin Oncol Date: 2002-08-01 Impact factor: 44.544
Authors: Fred Okuku; Elizabeth M Krantz; James Kafeero; Moses R Kamya; Jackson Orem; Corey Casper; Warren Phipps Journal: J Acquir Immune Defic Syndr Date: 2017-04-15 Impact factor: 3.731
Authors: Ramya Ramaswami; Thomas S Uldrick; Mark N Polizzotto; Kathleen M Wyvill; Priscila Goncalves; Anaida Widell; Kathryn Lurain; Seth M Steinberg; William Douglas Figg; Giovanna Tosato; Denise Whitby; Robert Yarchoan Journal: Clin Cancer Res Date: 2019-04-12 Impact factor: 12.531
Authors: E Mwinjiwa; P Isaakidis; R Van den Bergh; A D Harries; K D Bezanson; T Beyene; C Thompson; M Joshua; H Akello; M van Lettow Journal: Public Health Action Date: 2013-06-21
Authors: Mark N Polizzotto; Thomas S Uldrick; Kathleen M Wyvill; Karen Aleman; Vickie Marshall; Victoria Wang; Denise Whitby; Stefania Pittaluga; Elaine S Jaffe; Corina Millo; Giovanna Tosato; Richard F Little; Seth M Steinberg; Irini Sereti; Robert Yarchoan Journal: Clin Infect Dis Date: 2015-12-12 Impact factor: 9.079